SSX2 and synovial sarcoma: SSX2 was originally identified as part of a genomic translocation present in synovial sarcoma [15], [16] and later found to be identical to HOM-MEL-40, an immunogenic protein known to induce spontaneous antibody responses in 10% of patients with melanoma [17].